Thomas Pope, MD
Pediatrics · Smithfield, VANPI 1689655565
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 403 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Novo Nordisk at 24.6% of the total. Among pediatrics clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 403 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- Lilly USA, LLC$567
- AbbVie$507
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$403
- Merck$338
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,716100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 108 | $1,657 |
| AstraZeneca | 50 | $1,230 |
| Lilly USA, LLC | 41 | $567 |
| AbbVie(2 entities) | 36 | $507 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $403 |
| Merck | 26 | $338 |
| Johnson & Johnson | 18 | $301 |
| GSK | 10 | $171 |
| Astellas Pharma US Inc | 8 | $154 |
| Boehringer Ingelheim | 8 | $147 |
| Boston Scientific | 5 | $136 |
| Abbott | 5 | $125 |
| Sanofi-aventis U.S. LLC | 6 | $104 |
| Corium, LLC | 8 | $104 |
| Pfizer | 6 | $88 |
| Biohaven Pharmaceuticals, Inc. | 4 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $73 |
| Amarin Pharma, Inc. | 4 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $56 |
| Mylan Specialty L.p. | 3 | $49 |
| Amgen | 2 | $43 |
| Irhythm Technologies, Inc. | 1 | $39 |
| Dexcom, Inc. | 2 | $36 |
| Exact Sciences | 2 | $35 |
| Cranial Technologies, Inc | 1 | $34 |
| Shire North American Group Inc | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $21 |
| Sobi, Inc | 1 | $20 |
| Medicure Pharma Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,722 in reported general payments places this provider in the 95th percentile of 1,542 pediatrics providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $119,327 |
| EliquisApixaban | 57 | $78,634 |
| JardianceEmpagliflozin | 27 | $42,793 |
| FarxigaDapagliflozin Propanediol | 33 | $41,570 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $41,192 |
| JanuviaSitagliptin Phosphate | 30 | $39,519 |
| XareltoRivaroxaban | 36 | $32,431 |
| MyrbetriqMirabegron | 16 | $19,537 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 27 | $19,088 |
| MounjaroTirzepatide | 12 | $17,593 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $7,106 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $4,301 |
| Levothyroxine Sodium | 240 | $3,701 |
| Atorvastatin Calcium | 363 | $3,647 |
| Tamsulosin Hcl | 155 | $3,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,657 | $119,32772 claims |
| PfizerEliquis, Paxlovid | $88 | $81,49269 claims |
| MerckJanuvia, Janumet Xr | $338 | $58,60757 claims |
| Boehringer IngelheimJardiance | $147 | $42,79327 claims |
| AstraZenecaFarxiga | $1,230 | $41,57033 claims |
| GSKTrelegy Ellipta | $171 | $41,19245 claims |
| Johnson & JohnsonXarelto | $301 | $32,43136 claims |
| Astellas Pharma US IncMyrbetriq | $154 | $19,53716 claims |
| Lilly USA, LLCMounjaro | $567 | $17,59312 claims |
| AbbVieSynthroid | $507 | $2,85167 claims |
| Sanofi-aventis U.S. LLCLantus | $104 | $1,65514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,542 pediatrics providers in Virginia.
Other pediatrics in Smithfield
- Patricia MulreanyMidlothian$1.5M
- Dominick PastoreRichmond$1.1M
- Judith GrossbergMidlothian$291K
- Elizabeth CullenMidlothian$289K
- Martha SaundersMidlothian$288K
- Anne Marie IraniRichmond$265K
- Ozlem Goker-AlpanFairfax$210K
- Tamara SutherlandGlen Allen$145K
- Tamara Charity-BrownPetersburg$145K
- Alan RogolCharlottesville$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.